KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inovio Pharmaceuticals (INO) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Inovio Pharmaceuticals (INO) over the last 17 years, with Q3 2025 value amounting to $21.2 million.

  • Inovio Pharmaceuticals' Operating Expenses fell 2244.09% to $21.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $89.9 million, marking a year-over-year decrease of 2485.16%. This contributed to the annual value of $112.6 million for FY2024, which is 2221.1% down from last year.
  • Per Inovio Pharmaceuticals' latest filing, its Operating Expenses stood at $21.2 million for Q3 2025, which was down 2244.09% from $23.1 million recorded in Q2 2025.
  • Inovio Pharmaceuticals' 5-year Operating Expenses high stood at $106.3 million for Q4 2021, and its period low was $20.5 million during Q4 2024.
  • Its 5-year average for Operating Expenses is $47.8 million, with a median of $37.3 million in 2023.
  • As far as peak fluctuations go, Inovio Pharmaceuticals' Operating Expenses surged by 20454.58% in 2021, and later plummeted by 6448.11% in 2023.
  • Inovio Pharmaceuticals' Operating Expenses (Quarter) stood at $106.3 million in 2021, then plummeted by 47.28% to $56.1 million in 2022, then tumbled by 50.96% to $27.5 million in 2023, then fell by 25.49% to $20.5 million in 2024, then rose by 3.53% to $21.2 million in 2025.
  • Its last three reported values are $21.2 million in Q3 2025, $23.1 million for Q2 2025, and $25.1 million during Q1 2025.